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ABSTRACT 
Objective: Methanol-induced optic neuropathy is a visual impairment that results from damage to the optic nerve fibers caused by methanol. It is 
frequently bilateral with permanent visual deterioration. According to the American Academy of Clinical Toxicology (AACT), methanol-poisoned 
patients who present with ocular manifestations should be treated with fomepizole, ethanol, or hemodialysis, which do not remove the metabolites 
from the optic nerve. High-dose intravenous steroid treatment has been proposed in several studies to salvage vision because of its anti-
inflammatory effect. This article examines the existing literature on the efficacy of high-dose intravenous steroid treatment in patients with 
methanol-induced optic neuropathy. 
Methods: Literature searches were conducted using keywords and MeSH headings specifically chosen to identify published articles in CENTRAL, 
PubMed, ScienceDirect, ProQuest, EBSCO, and Google Scholar. Articles included were full-text, observational studies or randomized controlled trials 
published in English or Bahasa Indonesia. 
Results: Four case series and one case report were found in the bibliographic databases. We identified 33 patients with bilateral optic neuropathy 
caused by methanol ingestion who were initially treated with 1 g intravenous methylprednisolone, administered as a single dose or as divided doses 
for 3–4 d, followed by oral prednisolone. There were visual improvements in 48 out of 56 patients (83%). No adverse events were reported. 
Conclusion: Intravenous high-dose steroid treatment may benefit the visual status of patients with methanol-induced optic neuropathy. However, 
further studies are needed to determine the characteristics of patients who may benefit most from this regimen. 
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INTRODUCTION 
Toxic optic neuropathy is a visual impairment caused by damage to 
the optic nerve by several toxins, including drugs (ethambutol, 
isoniazid, antineoplastic drugs), metals (lead, mercury, and 
thallium), organic solvents, methanol, and carbon monoxide. 
Methanol is one of the most common etiologies reported [1]. 
According to a study by Yunard at Cipto Mangunkusumo General 
Hospital (Jakarta), the prevalence of methanol-induced toxic 
neuropathy in Indonesia is 31 cases in 2 y (2013–2014) [2]. At 
Sanglah General Hospital (Bali), the prevalence reported is 76 cases 
in 1 y (mid 2009–2010) [3]. 
Methanol is one of the simplest alcohol forms (CH3
The first treatment is to assess and maintain airways, breathing, and 
circulation. According to the AACT, patients with methanol-induced 
toxic optic neuropathy should be treated with sodium bicarbonate 
(if the pH is below 7.3), fomepizole, or ethanol to delay metabolism 
of methanol to formic acid and to prevent its accumulation. 
Hemodialysis is indicated in metabolic acidosis, vision loss, and 
organ damage, to enhance the removal of methanol and its 
metabolites [4, 5]. 
OH), boils at 64.5 
°C, and has a molecular weight of 32 g/mol. It is a clear, colorless, 
volatile, flammable liquid that has a faint, slightly alcoholic odor [4]. 
In several developing countries, methanol is consumed mainly as a 
homemade alcoholic beverage by people with low socioeconomic 
status. Methanol poisoning mostly occurs via oral ingestion of 
adulterated liquors, or by inhalation. Clinical characteristics of 
methanol poisoning are varied, but are usually limited to the central 
nervous system, eyes, and the gastrointestinal tract. The 
ophthalmologic symptoms are blurred vision, decreased visual 
acuity, photophobia, central scotoma, and blindness. Ocular 
examinations reveal mydriasis, hyperemia and edema of the optic 
disc, retinal edema, and optic atrophy [1, 4, 5]. 
In acute cases, methanol-induced toxicity is mostly caused by 
inflammation. High-dose intravenous steroid treatment followed 
by oral steroids have been proposed in several studies to salvage 
vision because of their anti-inflammatory effect. Steroids will 
reduce retinal inflammation and edema of the optic nerve, thus 
preventing permanent blindness [6]. However, the efficacy of high-
dose steroid use remains controversial. In this article, we examine 
the existing literature to evaluate the efficacy of high-dose 
intravenous steroid treatment in patients with methanol-induced 
optic neuropathy. 
MATERIALS AND METHODS 
Literature search strategy 
The literature search was performed using databases including 
CENTRAL, PubMed, Science Direct, ProQuest, and EBSCO. The search 
engine Google Scholar was also utilized. We included studies of any 
design. The literature review was conducted by using the following 
search terms: “methanol” and “optic,” in the title and abstract, 
combined with “steroid,” “prednisone,” or “methylprednisolone” in 
any field, and no time limits were set (the search contained articles 
published up until September 12, 2018). Bibliographic reference 
lists of articles found during the screening were searched manually 
to discover studies that were not identified in the search of the 
electronic literature databases. 
Inclusion and exclusion criteria 
Two authors (NP and NAR) independently screened titles and 
abstracts to select studies likely to provide relevant data. We 
retrieved and examined the full text of the selected studies 
independently for compliance with eligibility criteria. We included 
all human studies in patients diagnosed with toxic optic neuropathy 
induced by methanol ingestion who had received high-dose 
intravenous steroid treatment. Another inclusion criterion was that 
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the studies were written in English or Bahasa Indonesia. For this 
study, high-dose intravenous steroid treatment was defined as 1 g 
intravenous methylprednisolone daily, as a single dose or divided 
into multiple doses, given for any duration. The outcome variables of 
the therapeutic effect, which is the improvement in visual acuity 
after treatment, included hand movement, counting fingers, or 
improvement in reading line one of the Snellen chart, and were 
collected in follow-up visits. We excluded studies that described 
treatment regimens consisting of hemodialysis, ethanol, fomepizole, 
or sodium bicarbonate, or studies that did not report outcomes as 
mentioned above. 
Data extraction 
We extracted data from selected studies. Data included study design, 
patient characteristics (age, gender), intervention given (the dosage, 




A total of five studies were identified for inclusion in the review. The 
search of the CENTRAL, PubMed, ScienceDirect, ProQuest, and EBSCO 
databases provided a total of 215 citations, while other additional 
searches using Google Scholar provided a total of 138 citations. After 
adjusting for duplicates, 271 studies remained. Of these, 251 studies 
were discarded after reviewing the abstracts, because these articles did 
not meet the eligibility criteria. Eight additional studies were discarded, 
because the full text was not available. The full text of the remaining 12 
citations was examined in more detail. It appeared that seven studies did 
not meet the described inclusion criteria. Five studies met the inclusion 
criteria and were included in the systematic review. There were no 
additional studies in the references of the selected articles that met the 
inclusion criteria. We identified nonrandomized controlled trials or 
systematic reviews in our search. See flow diagram, fig. 1. 
Study characteristics 
The five studies finally selected for this review included three case 
series and one case report published in English, and also one case 
series published in Bahasa Indonesia. The duration of high-dose 
intravenous steroid treatment was 3–4 d in all studies. The included 
studies involved 33 participants. Two studies were conducted in 
Indonesia, and the other studies were conducted in India, Nepal, and 
the USA. Studies included in this systematic review were conducted 
by Yunard et al. (2016), Grecia et al. (2016), Sharma et al. (2012), 
Koehrer et al. (2011), and Shukla and Shikoh (2006) [2, 7-10]. 
In all studies, the primary outcome assessed was visual 
improvement from baseline. The timing of collecting the outcome 
measures varied among the studies, from 3 mo to 1 y. Secondary 
outcomes included changes in the optic disc and adverse events of 
the treatment. Two studies, including the studies by Koehrer et al. 
(2011) and Shukla and Shikoh (2006), evaluated changes of the 
optic disc. Two studies by Sharma et al. (2012), Shukla and Shikoh 
(2006) reported adverse events of the treatments table 1. 
Outcome measures 
When we combined the results of all case series, the treatment was 
effective in about 83% of cases (table 2). Changes to the optic disc 
are shown in table 1. No adverse effects were reported. 
 
Table 1: Summary of included studies evaluating the efficacy of high-dose intravenous steroid treatment of methanol-induced optic 
neuropathy 
Author, year 
of  publication 
Study 
design 
n Study population Intervention Outcome 
measures 
Result 
Age (y) Sex 




n = 13 
(of 31 
patients) 
N/A Male Intravenous high-dose MP Visual acuity 
improvement 
Visual acuity improvement 
(eyes): 
Improvement: 14 
No change: 3 
Worsening: 1 
LFU: 4 patients 




n = 1 46 Male 500 mg IV MP twice a day 
for 4 d; followed by 75 mg 
oral prednisolone for the 
first 4 mo and 50 mg for 
the next 4 mo 
Visual acuity Baseline: Visual acuity was 
light perception in right eye 
and 20/800 in left eye. 
Final: Visual acuity was finger 
count at 5 cm in right eye and 
20/400 in left eye. 




n = 1 
(of 8 
patients) 
60 Female 500 mg MP in 200 ml RL IV 
administration over 2 h 
twice a day for 3 d; followed 
by oral prednisolone 1 
mg/kg/day for 11 d 
Visual acuity and 
side effects of the 
treatment 
-Visual acuity  
Baseline: NLP bilateral 
1 y: HM bilateral 






n = 1 
(of 2 
patients) 
37 Male 1 g IV MP once daily for 3 
d; followed by oral 
prednisolone 
Visual acuity and 
fundus 
examination 
-Visual acuity unchanged. 
-Fundus examination 
Baseline: Bilateral papilledema. 
The optic nerve head showed 
slight temporal pallor with a 
swollen contour. 
3 mo: Bilateral optic atrophy 





n = 17 
(of 17 
patients) 
22–42 NA 1 g IV MP in 500 ml RL over 
2 h for 3 d; followed by 40 
mg oral prednisolone for 14 





-Visual outcome in 3 mo 
(patients): 
Improvement: 15 
No change: 1 
Late deterioration: 1 
-Funduscopy (at day 7): decrease 
in peripapillary and disc edema 
in most of the treated eyes. 
-There is no complication 
CDR, Cup-to-disc ratio; HM, Hand movement; LFU, Lost to follow-up; MP, Methylprednisolone; NLP, No light perception; RL, Ringer’s lactate 
solution; RNFL, Retinal nerve fiber layer 
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Fig. 1: PRISMA flowchart of literature search 
 
Table 2: Rates of visual improvement in patients following high-dose intravenous steroid treatment 
Author, Year of publication Visual improvement % (n/N eyes) 
Yunard et al., 2016  77 (14/18) 
Grecia et al., 2016 100 (2/2) 
Sharma et al., 2012 100 (2/2) 
Koehrer et al., 2011  0 (0/2) 
Shukla and Shikoh, 2006  88 (30/34) 
n, Number of eyes with visual improvement; N, Total eyes 
 
DISCUSSION 
Methanol is metabolized in the liver to formaldehyde by alcohol 
dehydrogenase, then to formic acid by formaldehyde 
dehydrogenase, and then, ultimately, to its end products, water and 
carbon dioxide. Formaldehyde is rapidly metabolized, but formic 
acid is slowly metabolized and, as a result, it accumulates and 
exceeds the body’s capacity to eliminate it. Formic acid is a 
metabolite that causes ocular toxicity. It specifically targets the optic 
disc and retrolaminar section, which are vulnerable to histotoxic 
hypoxia. Binding of formic acid and cytochrome oxidase might 
disrupt the function of the mitochondria in the optic nerve, thus 
causing depletion of adenosine triphosphate in the optic nerve. 
Hypoxia causes myelin sheath damage, nerve conduction deficit, and 
axoplasmic flow stasis. The optic nerve fiber and, consequently, the 
optic disc start to swell, resulting in loss of vision [8, 11-13]. Visual 
impairment commonly occurs 12–24 h after exposure [5, 6]. 
Permanent blindness may occur with ingestion of 10 ml methanol; 
the smallest reported amount to cause blindness is 4 ml [2, 5]. 
On the Asian subcontinent, methanol poisoning remains frequent, 
especially in poor socioeconomic groups where methanol is 
occasionally diluted in local spirits or used as a homemade alcoholic 
beverage. The characteristic demographics from all studies, except 
the study conducted by Shukla and Shikoh (2006), showed that 94% 
of the patients were male. This finding is similar to results of studies 
by Triningrat et al. (2010) and Samanta et al. (2012) [3, 14]. 
According to the World Health Organization, more males than 
females consume alcohol in all regions [15]. Despite similar amounts 
of alcohol consumption, more dopamine release was found in the 
ventral striatum compared to other striatal subregions, which is 
correlated with pleasure, reinforcement, and addiction formation. 
This may contribute to a subject’s positive effects of alcohol 
intoxication [16]. Age ranges from 22 to 60 y were reported in the 
study population of methanol poisoning studies conducted by Desai 
et al. (2013) and Paasma et al. (2009) [17, 18]. Additionally, Paasma 
et al. (2009) also observed that the population that drank most 
frequently comprises middle-aged males who are emotionally 
instable, highly curious, and sensation seeking, with low resistance 
to social pressure [18]. 
In four articles, the baseline visual acuity of the patients was mostly 
categorized as blind (<3/60). The prognosis of the visual outcome is 
mostly correlated with the severity of the metabolic acidosis and the 
serum methanol concentrations [1]. Therefore, according to the AACT, 
patients with metabolic acidosis should be treated with sodium 
bicarbonate and hemodialysis, and all patients should be given 
fomepizole or ethanol to delay metabolism of methanol to formic acid 
and to prevent its accumulation [4]. In all studies examined here, 
metabolic acidosis has been ruled out, but no methanol serum 
concentrations were reported. In the studies, visual improvements were 
seen in 83% of the eyes of all patients in the final follow-up. 
In the acute phase of toxic optic neuropathy induced by methanol 
intoxication, most patients have a normal-appearing optic disc, but 
hyperemia and swelling might occur and result in a papilledema-like 
appearance, similar to the findings in the study by Koehrer et al. 
(2011) [6, 10]. Different studies reported varying outcomes after 
high-dose steroid treatment. A study conducted by Shukla and 
Shikoh (2006) reported that most patients in the study showed a 
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decrease of optic disc swelling, which is relevant to the study by 
Zhao et al. (2015) [10, 19]. However, a study by Koehrer et al. 
(2011) showed different results. The baseline fundus examination 
showed a slight temporal pallor of the optic nerve, which is a sign of 
optic atrophy [9]. There is no treatment to reverse atrophy of the 
optic nerve, only treatment to limit further optic nerve damage (if 
possible). Regular consumption of alcohol by the patient may have 
contributed to the poor outcome in this study. 
High-dose intravenous pulse steroid treatment, using an anti-
inflammatory, neuroprotective, and immunosuppressant agent has 
clinical benefits, is effective for other types of optic neuropathies, 
including optic neuritis and traumatic optic neuropathy. Methanol 
toxicity in acute cases is mostly caused by inflammation [13, 19-21]. 
Bhalsing et al. (2017) reported that high-dose steroid treatment might 
reduce edema of the optic nerve sheaths, resulting in good recovery of 
vision and preventing permanent blindness. Meanwhile, other 
treatments could not remove the metabolites from the optic nerve [6]. 
Several studies reported that it is important to start treatment as 
soon as possible. Intravenous methylprednisolone given 6 d after 
methanol ingestion is not effective in improving vision [3, 11]. Only 
three studies reported the interval between methanol consumption 
and the start of the treatment, which ranged from 3 to 45 d. Delayed 
treatment and signs of optic atrophy at the initial clinical 
presentation may result in bad outcomes. 
Steroid treatment inhibits the immune system and the inflammatory 
response, thus increasing the risk of infection or reactivation of 
latent infection. However, no adverse event was found in two 
studies, which reported similar results as the article by Surhio et al. 
(2013) [22]. After confirming the diagnosis of methanol-induced 
optic neuropathy, chest X-ray, stool exam, tuberculin skin test, and 
internist consult for initiation of corticosteroid therapy might be 
done to prevent the potential risk of high-dose corticosteroid 
therapy. Steroid dosages were tapered off in all studies to prevent 
withdrawal effects after high-dose steroid administration [22]. 
LIMITATIONS 
Based on current evidence, a clear recommendation on the use of 
high-dose corticosteroids for treatment of methanol-induced optic 
neuropathy cannot be made. Studies are few in number and are of 
poor methodological quality. In the articles included in this review, 
we found that 83% of eyes had improvements in the visual acuity. 
However, it must be noted that these five studies are prospective 
case series or case reports. We found no RCT or systematic reviews. 
Unfortunately, many case reports and case series lack an informative 
abstract and title; thus, we may have possibly missed some studies. 
However, we also performed manual searches to further identify 
publications relevant to our study. Case series and case reports also 
have a publication bias that tends to publish only positive results. 
CONCLUSION 
Most patients in this study presented with blindness. High-dose 
intravenous methylprednisolone can be used to improve visual 
outcome in methanol-induced optic neuropathy. There were no 
adverse events reported in the examined studies; however, 
contraindications need to be carefully considered for safety reasons. 
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